Human immunodeficiency virus and hepatitis C virus coinfection in Nepal

Indian Journal of Gastroenterology

Volumn 33, Issue 2, 2014, Pages 141-145

  Barnawal, Satish Prasad ^a   Niraula, Surya Raj ^a   Agrahari, Anand Kumar ^a   Bista, Nikesh ^a   Jha, Nilambar ^a   Pokharel, Paras Kumar ^a  

^a B P KOIRALA INSTITUTE OF HEALTH SCIENCES   (Nepal)

Author keywords

Intravenous drug use; Retroviruses

Indexed keywords

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CROSS-SECTIONAL STUDY; FEMALE; FOLLOW UP; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PREVALENCE; QUESTIONNAIRE; RISK; VIRUS TRANSMISSION; COINFECTION; HIV INFECTIONS; IMMUNOLOGY; NEPAL; SEX DIFFERENCE; SUBSTANCE ABUSE; TIME;

ANTIRETROVIRUS AGENT;

ADULT; ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; COINFECTION; CROSS-SECTIONAL STUDIES; FEMALE; HEPATITIS C; HIV INFECTIONS; HUMANS; MALE; NEPAL; PREVALENCE; SEX FACTORS; SUBSTANCE ABUSE, INTRAVENOUS; TIME FACTORS;

EID: 84897094485     PISSN: 02548860     EISSN: 09750711     Source Type: Journal    
DOI: 10.1007/s12664-013-0407-1     Document Type: Article

References (39)

1. Anbazhagan GK, Krishnamoorthy S, Thiyagarajan T. Seroprevalence of HCV and its co-infection with HBV and HIV among liver disease patients of South Tamil Nadu. World J Hepatol. 2010;2: 42-8.
2. Soriano V, Sulkowski M, Bergin C, et al. Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV±HCV International Panel. AIDS. 2002;16: 813-28.
3. Mehta SH, Thomas DL, Sulkowski MS, et al. A framework for understanding factors that affect access and utilization of treatment for hepatitis C virus infection among HCV-mono-infected and HIV/HCV-co-infected injection drug users. AIDS. 2005;19: S179-89.
4. Annual Report, Department of Health Services. Government of Nepal, Ministry of Health and Population, Department of Health Services, Kathmandu. 2009/2010: 4.
5. Todd CS, Abed AMS, Strathdee SA, et al. HIV, hepatitis C, and hepatitis B infections and associated risk behavior in injection drug users, Kabul, Afghanistan. Emerg Infect Dis. 2007;13: 1327-31.
6. Qian HZ, Vermund SH, Kaslow RA, et al. Co-infection with HIV and hepatitis C virus in former plasma/blood donors: challenge for patient care in rural China. AIDS. 2006;20: 1429-35.
7. Law WP, Duncombe CJ, Mahanontharit A, et al. Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort. AIDS. 2004;18: 1169-77.
8. Thomas DL, Leoutsakas D, Zabransky T, Kumar MS. Hepatitis C in HIV-infected individuals: cure and control, right now. J Int AIDS Soc. 2011;14: 22-9.
9. Schnuriger A, Dominguez S, Guiguet M, et al. Acute hepatitis C in HIV-infected patients: rare spontaneous clearance correlates with weak memory CD4 T-cell responses to hepatitis C virus. AIDS. 2009;23: 2079-89.
10. Sullivan PS, Hanson DL, Teshale EH, et al. Effect of hepatitis C infection on progression of HIV disease and early response to initial antiretroviral therapy. AIDS. 2006;20: 1171-9.
11. Soriano V, Puoti M, Sulkowski M, et al. Care of patients with hepatitis C and HIV co-infection. AIDS. 2004;18: 1-12.
12. Spradling PR, Richardson JT, Buchacz K, et al. Trends in hepatitis C virus infection among patients in the HIV outpatient study, 1996-2007. J Acquir Immune Defic Syndr. 2010;53: 388-96.
13. Hatano H, Delwart EL, Norris PJ, et al. Evidence of persistent low-level viremia in long-term HAART-suppressed, HIV-infected individuals. AIDS. 2010;24: 2535-9.
14. Sighem A, Danner S, Ghani AC, et al. Mortality in patients with successful initial response to highly active antiretroviral therapy is still higher than in non-HIV-infected individuals. J Acquir Immune Defic Syndr. 2005;40: 212-8.
15. Peters L, Mocroft A, Soriano V, et al. Hepatitis C virus coinfection does not influence the CD4 cell recovery in HIV-1-infected patients with maximum virologic suppression. J Acquir Immune Defic Syndr. 2009;50: 457-63.
16. George SL, Gebhardt J, Klinzman D, et al. Hepatitis C virus viremia in HIV-infected individuals with negative HCV antibody tests. J Acquir Immune Defic Syndr. 2002;31: 154-62.
17. Victoria MB, Victoria FS, Torres KL, et al. Epidemiology of HIV/HCV coinfection in patients cared for at the Tropical Medicine Foundation of Amazonas. Braz J Infect Dis. 2010;14: 135-9.
18. Hagan H, Thiede H, Jarlais DCD. HIV/hepatitis C virus co-infection in drug users: risk behavior and prevention. AIDS. 2005;19: S199-207.
19. Jobarteh M, Malfroy M, Peterson I, et al. Seroprevalence of hepatitis B and C virus in HIV-1 and HIV-2 infected Gambians. Virol J. 2010;7: 230-40.
20. Sulkowski MS, Mehta SH, Torbenson MS, et al. Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults. AIDS. 2007;21: 2209-16.
21. Shafran SD. Early Initiation of antiretroviral therapy: the current best way to reduce liver-related deaths in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr. 2007;44: 551-6.
22. Luetkemeyer A, Hare CB, Stansell J, et al. Clinical presentation and course of acute hepatitis C infection in HIV-infected patients. J Acquir Immune Defic Syndr. 2006;41: 31-6.
23. + T-lymphocyte progression in HIV-HCV coinfection before and after antiretroviral therapy. AIDS. 2010;24: 1857-65.
24. Gras L, Kesselring AM, Griffin JT, et al. CD4 cell counts of 800 cells/mm3 or greater after 7 years of highly active antiretroviral therapy are feasible in most patients starting with 350 cells/mm3 or greater. J Acquir Immune Defic Syndr. 2007;45: 183-92.
25. Braitstein P, Justice A, Bangsberg DR, et al. Hepatitis C coinfection is independently associated with decreased adherence to antiretroviral therapy in a population-based HIV cohort. AIDS. 2006;20: 323-31.
26. Braitstein P, Palepu A, Dieterich D, et al. Special considerations in the initiation and management of antiretroviral therapy in individuals co-infected with HIV and hepatitis C. AIDS. 2004;18: 2221-34.
27. Backus LI, Boothroyd D, Deyton LR. HIV, hepatitis C and HIV/hepatitis C virus co-infection in vulnerable populations. AIDS. 2005;19: S13-9.
28. Richardson JL, Nowicki M, Danley K, et al. Neuropsychological functioning in a cohort of HIV and hepatitis C virus-infected women. AIDS. 2005;19: 1659-67.
29. Rosenberg SD, Drake RE, Brunette MF, et al. Hepatitis C virus and HIV co-infection in people with severe mental illness and substance use disorders. AIDS. 2005;19: S26-33.
30. Gupta S, Singh S. Occult hepatitis B virus infection in ART-naïve HIV-infected patients seen at a tertiary care centre in north India. BMC Infect Dis. 2010;10: 53-9.
31. Kuniholm MH, Mark J, Aladashvili M, et al. Risk factors and algorithms to identify hepatitis C, hepatitis B, and HIV among Georgian tuberculosis patients. Int J Infect Dis. 2008;12: 51-6.
32. Mehta SH, Lucas GM, Mirel LB, et al. Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic. AIDS. 2006;20: 2361-9.
33. Merchante N, Giro'n-Gonza'lez JA, Serrano MG, et al. Survival and prognostic factors of HIV-infected patients with HCV-related end-stage liver disease. AIDS. 2006;20: 49-57.
34. Beyrer C, Wirtz AL, Baral S, et al. Epidemiologic links between drug use and HIV epidemics: an international perspective. J Acquir Immune Defic Syndr. 2010;55: S10-6.
35. Garfein RS, Golub ET, Greenberg AE, et al. A peer-education intervention to reduce injection risk behaviors for HIV and hepatitis C virus infection in young injection drug users. AIDS. 2007;21: 1923-32.
36. Neaigus A, Gyarmathy VA, Miller M, et al. Injecting and sexual risk correlates of HBV and HCV seroprevalence among new drug injectors. Drug Alcohol Depend. 2007;89: 234-43.
37. Hagan H, Jarlais DCD, Friedman SR, et al. Reduced risk of hepatitis B and hepatitis C among injection drug users in the Tacoma Syringe Exchange Program. Am J Public Health. 1995;85: 1531-7.
38. Kontorinis N, Agarwal K, Dieterich DT. Treatment of hepatitis C virus in HIV patients: a review. AIDS. 2005;19: S166-73.
39. McGovern BH. Hepatitis C, in the HIV-infected patient. J Acquir Immune Defic Syndr. 2007;45: S47-56.